(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on chronic disease, translational and precision medicine research. Trends include multimodal imaging, AI analytics, advanced contrast agents and localized production.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Preclinical Imaging Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Preclinical Imaging Market to Reach $5.18 Billion by 2030 as Advanced Research Applications Expand
The global preclinical imaging market is experiencing strong growth, supported by increased biomedical research, expanding drug development programs, and rising demand for advanced disease-monitoring technologies. The market is projected to grow from $3.69 billion in 2025 to $3.93 billion in 2026, representing a compound annual growth rate (CAGR) of 6.7%.
Historical market growth has been driven by the increasing use of animal models in biomedical research, the expansion of oncology and neurology studies, and the wider adoption of non-invasive imaging techniques. Growth in preclinical drug testing activities and the availability of advanced imaging reagents have also strengthened demand for preclinical imaging systems and related technologies.
Looking ahead, the preclinical imaging market is forecast to reach $5.18 billion by 2030, expanding at a CAGR of 7.1%. Key growth factors include rising demand for real-time disease visualization, higher investment in translational research, the expansion of precision medicine studies, and the growing use of artificial intelligence-assisted image analysis. The increasing deployment of advanced contrast agents is also expected to support market development.
Prominent preclinical imaging market trends include the adoption of multimodal imaging platforms, increased use of high-resolution imaging systems, and closer integration of imaging technologies with data analytics. Longitudinal disease-monitoring studies are expanding, while research organizations are placing greater emphasis on translational imaging accuracy, workflow efficiency, and the reproducibility of results.
The growing global burden of chronic diseases is expected to be a major driver of preclinical imaging market growth. Imaging technologies enable researchers to visualize disease progression, evaluate structural and functional changes, and improve understanding of complex medical conditions. They also support the assessment of potential therapies before clinical trials begin. According to the World Health Organization, noncommunicable diseases accounted for 75% of all deaths globally as of February 2024, highlighting the need for continued investment in disease research and therapeutic development.
Innovation remains a central competitive strategy within the preclinical imaging industry. In September 2023, Revvity Inc. launched several next-generation imaging systems for a broad range of preclinical research applications. These included the IVIS Spectrum 2 and IVIS SpectrumCT 2 systems, the Quantum GX3 microCT imaging solution, and technology combining two-dimensional optical imaging with full three-dimensional imaging capabilities. The systems were designed to improve image-based performance, strengthen research capabilities, and enhance workflow efficiency.
Strategic acquisitions are also shaping the market. In February 2024, Bruker Corporation acquired Spectral Instruments Imaging for $37.5 million. The transaction expanded Bruker's capabilities in life sciences research and added specialized preclinical optical imaging technologies for bioluminescent, fluorescent, and X-ray applications. The acquisition reflects continued industry investment in advanced imaging portfolios and integrated research solutions.
North America was the largest region in the preclinical imaging market in 2025. The regions covered by the market analysis include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Modality: Optical Imaging Systems; Preclinical Nuclear Imaging Systems; Micro-Magnetic Resonance Imaging Systems; Micro-Ultrasound Systems; Micro-Computed Tomography Systems; Preclinical Photoacoustic Imaging Systems; Preclinical Magnetic Particle Imaging (MPI) Systems
2) By Reagents: Preclinical Optical Imaging Reagents; Preclinical Nuclear Imaging Reagents; Preclinical MRI Contrast Agents; Preclinical Ultrasound Contrast Agents; Preclinical CT Contrast Agents
3) By End User: Hospital; Diagnostics Center; Other End-User
Subsegments:
1) By Optical Imaging Systems: Bioluminescence Imaging; Fluorescence Imaging
2) By Preclinical Nuclear Imaging Systems: Positron Emission Tomography (PET); Single-Photon Emission Computed Tomography (SPECT)
3) By Micro-Magnetic Resonance Imaging (Micro-MRI) Systems: High-Resolution Micro-MRI Systems; Functional Micro-MRI Systems
4) By Micro-Ultrasound Systems: High-Frequency Ultrasound Imaging; Real-Time Micro-Ultrasound Systems
5) By Micro-Computed Tomography (Micro-CT) Systems: In Vivo Micro-CT Systems; Ex Vivo Micro-CT Systems
6) By Preclinical Photoacoustic Imaging Systems: Multi-Wavelength Photoacoustic Imaging; Hybrid Photoacoustic Imaging Systems
7) By Preclinical Magnetic Particle Imaging (MPI) Systems: MPI For Cell Tracking; MPI For Vascular Imaging
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment